In one month (after only the 1st desensitization routine), 67.7% of individuals got responded; in these responders, therapy reduced T-cell crossmatch (TCXM) from 122.4 91.4 to 24.7 19.4 median route change (MCS) and BFXM from 279 142.9 to 74.7 34.8 MCS. imperfect case Nrp2 reports. Bortezomib and eculizumab look like Continue Reading